# Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

Source: https://onco.cc/trials/nct05582538/  
OnCo record `nct05582538` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ceralasertib, durvalumab and nab-paclitaxel in triple-negative breast cancer, run by IFOM ETS - The AIRC Institute of Molecular Oncology, now recruiting.

## Summary

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel is a phase 2, interventional study registered as NCT05582538 by IFOM ETS - The AIRC Institute of Molecular Oncology, with a registry enrolment figure of 37 participants, started 2022-12-15 and due to reach its primary completion in 2027-12. Interventions recorded: Ceralasertib; Durvalumab; Nab-paclitaxel. Conditions listed: Triple Negative Breast Cancer Metastatic. Triple-negative eligibility wording from the registry: "Metastatic TNBC patients who have not received prior systemic cytotoxic therapy in the advanced setting and whose tumor have relapsed from treatment with curative intent for early disease, which must have included ICI and chemotherapy as part of radical locoregional therapy". Sites: Italy. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: ATRiBRAVE
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT05582538
- Phase: 2
- Setting: Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel: The ATRiBRAVE Trial
- Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT05582538: https://clinicaltrials.gov/study/NCT05582538

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/), [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Ceralasertib](https://onco.cc/drugs/ceralasertib/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Nab-paclitaxel](https://onco.cc/drugs/nab-paclitaxel/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05582538.json